Protodigm Announces Official Launch of Drug Development Company Skunkworks

LONDON, May 18, 2021 /PRNewswire/ — Protodigm, a first-of-its-kind life sciences contract skunkworks company, today announced its official launch, founded by CEO Mike Rea of IDEA Pharma. Protodigm offers its customers research, innovation and a universe of possibilities in which a drug could be brought to market.

“Protodigm offers pharmaceutical customers a new approach to drug development by exploring all options and establishing proven cases while avoiding risk,” said Rea. “We use a skunkworks approach to test and define what is approvable, what a drug might do, and what the market might want to do with it.”

Rea brings over 20 years of drug development expertise to Protodigm. As founder and CEO of IDEA Pharma, he helped lead eight of the top fifteen drug launches over the past five years. Having gained considerable notoriety among biotechnology and pharmaceutical professionals, it boasts of being included in lists such as: The medicine maker top 20 inspirational drug makers and most influential people in healthcare, PharmaPhorum’s among the top 10 innovators and a lifetime “Red Jacket Award” from PharmaVOICE as one of the 100 Most Inspiring People in Healthcare.

In addition to his leadership at Protodigm, Rea is the creator of IDEA Pharma’s annual Pharmaceutical Innovation Index, the coveted top spot for big pharma. He is also the author of the book “Positioning Pharmaceuticals”.

“Using what we learned at IDEA Pharma, we believe Protodigm will revolutionize the drug development process,” Rea said. “The pharmaceutical industry is just waiting to be changed. With a team of top biotech and pharma innovators, Protodigm will have the ambition, network and expertise to drive positive change in drug development.”

Rea added, “The key to understanding Protodigm’s services is understanding what it is: a skunkworks contract. Protodigm is not a consulting firm, contract research organization (CRO), think tank, or incubator. Skunkworks, a term used in business, engineering and technical fields, is a group within an organization, distinct from traditional R&D, whose purpose is to invent and innovate independently, without being hampered by bureaucracy. Inventing and innovating requires skills, techniques and, above all, knowing how to use them, which the Protodigm team is uniquely positioned to do.”

Rea joins Rea is a group of scientists with Ph.D. Oxford and Cambridgephysician and member of the FDA Scientific Advisory Board, drug development visionary who has authored over 70 scientific publications, big data analyst, logistics specialist, Harvard business school graduate, life science CEOs and executives, consulting executives, equity research veterans, and venture capitalists.

“Protodigm aims to avoid premature specialization in drug development,” Rea said. “We provide our customers with a map of all the likely ways to bring a drug to market before it enters clinical trials. We plan to reveal unexpected avenues to market, which will save our clients time and money while maximizing opportunities.

Learn more about Protodigm at

About Protodigm:

Protodigm is a contract skunkworks company that provides its clients with a research body to invent and innovate new assets. Protodigm applies skunkworks techniques to drug development, giving clients every possible development option by generating hypotheses and supporting evidence. This approach breaks the industry mold, as drug development is too often a high-risk, one-track process. If an asset fails, it can be devastating. With a skunkworks approach, assets can be developed with multiple parallel options in addition to their originally intended use, reducing innovation risks, saving time, money and effort.

Media contact:

Scott Stachowiak

Partners Russo LLC

[email protected]

+1 (646) 942-5630

SOURCE Protodigm

Related links

Comments are closed.